Cystatin C Predicts Incident Cardiovascular Disease in Twins
- PMID: 27353608
- PMCID: PMC4937258
- DOI: 10.1161/JAHA.115.003085
Cystatin C Predicts Incident Cardiovascular Disease in Twins
Abstract
Background: Cystatin C is associated with both renal function and atherosclerotic cardiovascular disease (ASCVD). We have previously shown a genetic correlation between cystatin C and prevalent ASCVD. The objective of this article is to study whether variation in cystatin C or creatinine predicts incident ASCVD when controlled for genetic factors.
Methods and results: The predictive value of cystatin C and creatinine for incident ASCVD was studied in 11 402 Swedish twins, free of CVD at baseline, in an adjusted Cox-regression model during a median follow-up of 71 months. Twin pairs discordant for incident stroke, myocardial infarction and ASCVD during follow-up were identified and within-pair comparisons regarding cystatin C and creatinine levels were performed. We also investigated whether contact frequency and degree of shared environment influences were associated with similarity in cystatin C levels. In univariate analysis, cystatin C predicted incident ASCVD hazard ratio 1.57, 95% CI 1.47-1.67. When adjusted for traditional Framingham risk factors as covariates, cystatin C remained a predictor of incident stroke hazard ratio 1.45, 95% CI (1.25-1.70), ASCVD hazard ratio 1.26, 95% CI (1.13-1.41), and myocardial infarction hazard ratio 1.16, 95% CI (1.01-1.33). In twins discordant for incident stroke, cystatin C at baseline was higher in the twin who experienced a stroke compared to the healthy co-twin (1.11±0.3 mg/L versus 1.06±0.3 mg/L), whereas creatinine was lower in the twin who developed CVD compared to their healthy co-twins (76.1±16.9 μmol/L versus 79.4±20.3 μmol/L).
Conclusions: Variation in cystatin C relates to incident ASCVD and to stroke when adjusted for genetic confounding. In identical twins, cystatin C may be a sensitive marker of early hypertensive end-organ damage and small-vessel disease, whereas creatinine level may reflect nutritional status. The findings in disease-discordant monozygotic twins indicate that unique, possibly preventable, environmental factors are important.
Keywords: cardiovascular disease; co‐twin‐control study; cystatin C; genetic epidemiology; myocardial infarction; stroke.
© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
Similar articles
-
Amino-Terminal Pro-B-Type Natriuretic Peptide Improves Discrimination for Incident Atherosclerotic Cardiovascular Disease Beyond Ambulatory Blood Pressure in Elderly Men.Hypertension. 2015 Sep;66(3):681-6; discussion 445. doi: 10.1161/HYPERTENSIONAHA.115.05717. Epub 2015 Jul 6. Hypertension. 2015. PMID: 26150437
-
Risks of Myocardial Infarction, Death, and Diabetes in Identical Twin Pairs With Different Body Mass Indexes.JAMA Intern Med. 2016 Oct 1;176(10):1522-1529. doi: 10.1001/jamainternmed.2016.4104. JAMA Intern Med. 2016. PMID: 27479111
-
Kidney dysfunction and fatal cardiovascular disease--an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study.Am Heart J. 2008 Jan;155(1):62-8. doi: 10.1016/j.ahj.2007.08.012. Epub 2007 Oct 24. Am Heart J. 2008. PMID: 18082491
-
Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.Am J Kidney Dis. 2021 Mar;77(3):386-396.e1. doi: 10.1053/j.ajkd.2020.09.015. Epub 2020 Nov 14. Am J Kidney Dis. 2021. PMID: 33197533
-
Long-Term Atherosclerotic Cardiovascular Disease Risk in Patients With Cancer: A Population-Based Study.Curr Probl Cardiol. 2023 Jul;48(7):101693. doi: 10.1016/j.cpcardiol.2023.101693. Epub 2023 Mar 15. Curr Probl Cardiol. 2023. PMID: 36924906 Review.
Cited by
-
Serum cystatin C predicts the risk of non-ST-elevation acute coronary syndrome.J Cardiothorac Surg. 2023 Dec 1;18(1):351. doi: 10.1186/s13019-023-02465-1. J Cardiothorac Surg. 2023. PMID: 38041201 Free PMC article.
-
Cathepsin B regulates hepatic lipid metabolism by cleaving liver fatty acid-binding protein.J Biol Chem. 2018 Feb 9;293(6):1910-1923. doi: 10.1074/jbc.M117.778365. Epub 2017 Dec 19. J Biol Chem. 2018. PMID: 29259130 Free PMC article.
-
Cystatin C as a biomarker of chronic kidney disease: latest developments.Expert Rev Mol Diagn. 2020 Oct;20(10):1019-1026. doi: 10.1080/14737159.2020.1768849. Epub 2020 May 25. Expert Rev Mol Diagn. 2020. PMID: 32450046 Free PMC article. Review.
-
Cystatin C Expression is Promoted by VEGFA Blocking, With Inhibitory Effects on Endothelial Cell Angiogenic Functions Including Proliferation, Migration, and Chorioallantoic Membrane Angiogenesis.J Am Heart Assoc. 2018 Nov 6;7(21):e009167. doi: 10.1161/JAHA.118.009167. J Am Heart Assoc. 2018. PMID: 30571388 Free PMC article.
References
-
- Onopiuk A, Tokarzewicz A, Gorodkiewicz E. Cystatin C: a kidney function biomarker. Adv Clin Chem. 2015;68:57–69. - PubMed
-
- Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:1359–1366. - PubMed
-
- Bengtsson E, Nilsson J, Jovinge S. Cystatin C and cathepsins in cardiovascular disease. Front Biosci. 2008;13:5780–5786. - PubMed
-
- Angelidis C, Deftereos S, Giannopoulos G, Anatoliotakis N, Bouras G, Hatzis G, Panagopoulou V, Pyrgakis V, Cleman MW. Cystatin C: an emerging biomarker in cardiovascular disease. Curr Top Med Chem. 2013;13:164–179. - PubMed
-
- Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606–1615. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical